United States: Federal Circuit Invalidates Galderma Differin Patents

In Galderma Laboratories v. Tolmar, Inc., the Federal Circuit reversed the district court's findings that the Orange Book-listed patents for Galderma's Differin® 0.3% gel product were not invalid as obvious. In so doing, the Federal Circuit took a narrow view of "unexpected results" that Judge Newman warns may "disincentivize" improvement patents in the field of medicine.

The Patents At Issue

The patents at issue were the five Orange Book-listed patents for Galderma's Differin® 0.3% gel product: U.S. Patent No. 7,579,377; U.S. Patent No. 7,737,181; U.S. Patent No. 7,834,060; U.S. Patent No. 7,838,558; and U.S. Patent No. 7,868,044.

The Federal Circuit identified claim 5 of the '558 patent are representative:

5. A topically applicable pharmaceutical composition comprising 0.3% by weight of [adapalene] relative to the total weight of the composition, effective for the treatment of acne, formulated into a topically applicable, pharmaceutically acceptable medium therefor, said composition being in the form of a topically applicable, pharmaceutically acceptable aqueous gel comprising at least one carbomer gelling agent and wherein the sole anti acne ingredient is adapalene.

The ANDA Litigation

The case stemmed from Tolmar's filing of an Abbreviated New Drug Application ("ANDA") seeking FDA approval of a generic version of Galderma's Differin® Gel 0.3% product. As noted by the Federal Circuit, the product "is a topical medication containing 0.3% by weight adapalene approved for the treatment of acne." Galderma brought suit in the U.S. District Court for the District of Delaware, which ultimately ruled in Galderma's favor.

The Asserted Prior Art

Tolmar asserted that the patents were obvious in view of three primary references: U.S. Patent No. 4,717,720 (referred to by the Federal Circuit as the "Shroot '720 patent"), U.S. Reissue Patent No. 34,440 (referred to by the Federal Circuit as the "Shroot '440 patent"), and the Differin® 0.1% Gel Data Sheet (referred to by the Federal Circuit as the "Data Sheet"). The 0.1% gel product had been approved about 10 years before the 0.3% gel product, and the Shroot patents had been listed in the Orange Book for the 0.1% gel product until they expired.

According to the Federal Circuit, the Shroot patents disclosed adapalene for use in treating acne, at concentrations "preferably between 0.01 and 1 weight percent," with examples of compositions with concentrations of 0.001%, 0.1%, and 1%. The Data Sheet disclosed the formulation for the 0.1% gel product, which includes inactive ingredients recited in the asserted claims, except that it listed "poloxamer 182," while certain asserted claims recited "poloxamer 124." (The district court determined that the two polaxamers were equivalent.)

Tolmar also cited other references testing a 0.3% adapalene composition in an animal model and disclosing a 0.3% adapalene composition for other purposes "without intolerable irritability."

The Federal Circuit Decision

The Federal Circuit decision was authored by Judge Prost and joined by Judge Bryson. Judge Newman authored a dissenting opinion.

Judge Prost begins her analysis with this summary statement:

Tolmar presents an obviousness case that is both straightforward and potent.

According to Judge Prost, because the prior art disclosed a range of adapalene concentrations that encompassed the claimed 0.3% amount, "the burden of production falls upon the patentee to come forward with evidence that (1) the prior art taught away from the claimed invention; (2) there were new and unexpected results relative to the prior art; or (3) there are other pertinent secondary considerations." Still, the "ultimate burden of proving obviousness rests with Tolmar."

No Teaching Away

Although the district court found "teaching away" in the discussion of the "dose-dependent increase in side effects," the Federal Circuit majority disagreed, because there was no teaching "that increasing the concentration to 0.3% would be unproductive," or "that the side effects would be serious enough to dissuade the development of a 0.3% adapalene product."

Although the district court found "teaching away" in the discussion of the 0.1% product as "optimal," the Federal Circuit majority disagreed, based on the principle that "[a] teaching that a composition may be optimal or standard does not criticize, discredit, or otherwise discourage investigation into other compositions."

Non-Probative Unexpected Results

While the district court found unexpected results in the "comparable tolerability" of the 0.1% and 0.3% products, the Federal Circuit majority determined that these unexpected results were "not probative of nonobviousness." In so doing, the majority drew a distinction between results that reflect a difference in degree(not probative) versus results that reflect a difference in kind(probative).

Unexpected results that are probative of nonobviousness are those that are "different in kind and not merely in degree from the results of the prior art." .... Results which differ by percentages are differences in degree rather than kind, where the modification of the percentage is within the capabilities of one skilled in the art at the time. Thus, where an unexpected increase in efficacy is measured by a small percentage, as here, and the evidence indicates that skilled artisans were capable of adjusting the percentage, the result constitutes a difference in degree, not kind. So too, where an increase by a percentage is expected but not found, that result is also likely only a difference in degree. In this case, the expected result was an increase, by some percentage, in the prevalence of certain side effects. The failure of that percent increase to materialize, though unexpected, constitutes only a difference in degree from the prior art results. Accordingly, the comparable tolerability of 0.1% and 0.3% adapalene does not indicate that the asserted claims are non-obvious.

Non-Probative Commercial Success

While the district court found evidence of commercial success in the fact that Tolmar and others had filed ANDA applications for the patented product, the Federal Circuit majority disagreed, noting:

The fact that Tolmar "believes that it can make a profit selling a generic version of the claimed invention" ... tells us very little about the level of commercial success of the patented invention relative to the prior art or the extent to which the commercial success of the branded drug is "due to the merits of the claimed invention."

While the district court found evidence of commercial success in the fact that the 0.3% product "quickly gained and maintained market share," the Federal Circuit majority determined that the commercial success was "of limited value in determining whether or not the presently asserted claims are obvious," because "market entry by others was precluded [due to blocking patents]," e.g., the Shroot patents.

Thus, the Federal Circuit reversed the district court and held "that claims 35 and 36 of the '181 patent, claims 24 and 27 of the '060 patent, claim 5 of the '558 patent, and claims 40 and 41 of the '044 patent are invalid as obvious."

Judge Newman's Dissent

Judge Newman filed a 17 page dissenting opinion that takes the majority to task for failing to give proper weight to the district court's factual findings and analysis, and "instead making their own findings, and applying flawed procedural and substantive law."

My colleagues do not identify clear error in the district court's findings; instead they distort the burdens of proof and production, ignore the applicable standard of proof and rely on their own factual determinations and creative theories of law, and eradicate the patent.

According to Judge Newman:

Particularly for close questions of patentability, the district court's findings and assessments of credibility and weight of evidence, and the district court's application of law to found facts, compel appellate attention. The role of the trial court in considering the evidence that each party provides through examination and cross-examination of witnesses and documents, with judicial elaboration and interaction, cannot be matched on appeal.

With regard to the analytical framework applied by the majority, and its burden-shifting, Judge Newman emphasized:

The district court correctly explained that "the proper analysis of obviousness under 35 U.S.C. §103 requires that 'all evidence relevant to obviousness or nonobviousness be considered, and be considered collectively,' without resortto presumptions of prima facie obviousness or burden-shifting.".... This is the correct standard, established in Graham v. John Deere and reiterated consistently and exhaustively.

Judge Newman presents a different view of the prior art, in a light indicating that the district court's determination was not clearly erroneous. With regard to Galderma's evidence of unexpected results, Judge Newman notes:

[B]ased on expert testimony from both sides, the district court found that "[w]hereas the prior art suggested a dose-dependent, clinically meaningful increase in side effects would result from increasing the concentration of adapalene from 0.03% to 0.1%, the claimed inventions achieved a difference in kind by discontinuing that trend." .... The district court explained that differences in degree occur when the invention is merely a continuation of a trend previously described in the prior art. ... Here, the prior art showed a trend to increased adverse side effects with increased concentration, while Galderma's products violated that trend. This was a difference in kind, not in degree.

The District Court's Legal Error?

The bulk of the majority decision does read like a de novo determination of validity. However, before Judge Prost commences her analysis of Galderma's objective evidence of non-obviousness, she notes this legal error in the district court's analysis:

Prior to addressing the obviousness of the asserted claims, we note an error in the district court's obviousness analysis. The district court framed the obviousness inquiry as requiring Tolmar to provide motivation in the prior art to triple the concentration of adapalene from 0.1% to 0.3%. ... Tolmar carried no such burden. .... Nothing in the statute or our case law requires Tolmar to prove obviousness by starting with a prior art commercial embodiment and then providing motivation to alter that commercial embodiment. .... This is particularly true where, as here, the prior art teaches a range that encompasses both the prior art commercial embodiment and the claimed invention.

Having found that the district court's determination rested on an incorrect legal footing, should the Federal Circuit have remanded the case for consideration under the proper legal framework?

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions